Download PDF

1. Company Snapshot

1.a. Company Description

Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments.The company offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics; and diagnostic second opinion, test directory, and clinical trials and R&D services.It uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.


The company also provides radiotherapy; and develops therapeutic modalities and diagnostic tools.The company was formerly known as Althia Health, S.L. and changed its name to Atrys Health, S.A. in May 2016.Atrys Health, S.A. was incorporated in 2007 and is headquartered in Madrid, Spain.

Show Full description

1.b. Last Insights on ATRY

Have nothing to say about that one ...

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (5.25%)

6. Segments

Prevention Medicine

Expected Growth: 5%

Atrys Health's Prevention Medicine segment growth is driven by increasing demand for early disease detection, government initiatives promoting preventive care, and advancements in AI-powered diagnostics. Additionally, the growing elderly population and rising healthcare expenditure are contributing to the 5% growth rate.

Diagnosis

Expected Growth: 4%

Atrys Health's 4-level growth is driven by increasing demand for diagnostic services, strategic partnerships, and expansion into new markets. The company's innovative diagnostic solutions, strong R&D investments, and efficient operational model also contribute to its growth. Additionally, the growing need for personalized medicine and the increasing adoption of digital health technologies further support Atrys Health's rapid expansion.

Oncology

Expected Growth: 7%

Atrys Health's Oncology segment growth is driven by increasing cancer prevalence, advancements in precision medicine, and rising demand for personalized treatment options. Additionally, strategic partnerships, expanded product offerings, and geographic expansion into high-growth markets contribute to the 7% growth rate.

7. Detailed Products

Radiation Oncology

Atrys Health provides radiation oncology services, offering personalized cancer treatment plans using advanced radiation therapy techniques.

Medical Physics

Atrys Health offers medical physics services, including radiation safety, quality control, and equipment calibration for healthcare facilities.

Radiation Protection

Atrys Health provides radiation protection services, including radiation monitoring, dosimetry, and shielding design for healthcare facilities and industries.

Nuclear Medicine

Atrys Health offers nuclear medicine services, including radiopharmaceutical development, production, and distribution.

Radiotherapy Equipment

Atrys Health provides radiotherapy equipment, including linear accelerators, treatment planning systems, and quality assurance devices.

Radiation Oncology Information Systems

Atrys Health offers radiation oncology information systems, including treatment planning, record and verify, and oncology information systems.

8. Atrys Health, S.A.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Atrys Health, S.A. operates in a niche market with limited substitutes, but there are some alternative solutions available, making the threat of substitutes medium.

Bargaining Power Of Customers

Atrys Health, S.A. has a diverse customer base, and no single customer has significant bargaining power, making the bargaining power of customers low.

Bargaining Power Of Suppliers

Atrys Health, S.A. relies on a few key suppliers for critical components, giving them some bargaining power, making the bargaining power of suppliers medium.

Threat Of New Entrants

The healthcare industry is highly regulated, and Atrys Health, S.A. operates in a niche market, making it difficult for new entrants to enter the market, but not impossible, making the threat of new entrants high.

Intensity Of Rivalry

Atrys Health, S.A. operates in a competitive market, but there are some barriers to entry, making the intensity of rivalry medium.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 43.92%
Debt Cost 6.00%
Equity Weight 56.08%
Equity Cost 6.00%
WACC 6.00%
Leverage 78.32%

11. Quality Control: Atrys Health, S.A. passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Idorsia

A-Score: 5.1/10

Value: 8.4

Growth: 6.8

Quality: 5.2

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Centessa Pharmaceuticals

A-Score: 3.9/10

Value: 6.0

Growth: 3.9

Quality: 4.7

Yield: 0.0

Momentum: 8.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Genus

A-Score: 3.9/10

Value: 1.7

Growth: 3.9

Quality: 4.7

Yield: 1.9

Momentum: 8.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Barinthus Bio

A-Score: 3.5/10

Value: 8.4

Growth: 4.8

Quality: 3.4

Yield: 0.0

Momentum: 4.5

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Atrys Health

A-Score: 2.7/10

Value: 6.0

Growth: 3.7

Quality: 1.9

Yield: 0.0

Momentum: 1.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Formycon

A-Score: 2.2/10

Value: 6.0

Growth: 2.2

Quality: 3.4

Yield: 0.0

Momentum: 0.0

Volatility: 1.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

2.71$

Current Price

2.71$

Potential

-0.00%

Expected Cash-Flows